Allogeneic Stem Cell Transplantation for Children With CML
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
In children and adolescents with chronic myeloid leukaemia (CML) stem cell transplantation
(SCT) may be a valid alternative to the life-long treatment with tyrosinkinase inhibitors
(TKI). This trial aims to evaluate the use of a reduced intensity conditioning regimen (RIC),
consisting of fludarabine, melphalan and thiotepa in order to minimize transplant related
mortality and toxic late effects. Strict post-transplant monitoring and reintroduction of TKI
as well as donor lymphocyte infusions (DLI) in case of relevant residual disease are part of
the protocol.